ATE541844T1 - Antivirale verbindungen - Google Patents

Antivirale verbindungen

Info

Publication number
ATE541844T1
ATE541844T1 AT06848055T AT06848055T ATE541844T1 AT E541844 T1 ATE541844 T1 AT E541844T1 AT 06848055 T AT06848055 T AT 06848055T AT 06848055 T AT06848055 T AT 06848055T AT E541844 T1 ATE541844 T1 AT E541844T1
Authority
AT
Austria
Prior art keywords
compounds
antiviral compounds
hcv
viral
syntheses
Prior art date
Application number
AT06848055T
Other languages
English (en)
Inventor
David Betebenner
David DEGOEY
Clarence MARING
Allan KRUEGER
Nobuhiko Iwasaki
Todd ROCKWAY
Curt COOPER
David Anderson
Pamela DONNER
Brian Green
Dale Kempf
Dachun Liu
Keith F Mcdaniel
Darold Madigan
Christopher Motter
John PRATT
Jason Shanley
Michael Tufano
Rolf Wagner
Rong Zhang
Akhteruzzaman Molla
Hongmei Mo
Tami Pilot-Matias
Sherie Masse
Robert Carrick
Weping He
Liangjun Lu
David GRAMPOVNIK
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE541844T1 publication Critical patent/ATE541844T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06848055T 2005-12-21 2006-12-20 Antivirale verbindungen ATE541844T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75247305P 2005-12-21 2005-12-21
US11/613,810 US7910595B2 (en) 2005-12-21 2006-12-20 Anti-viral compounds
PCT/US2006/049079 WO2007076034A2 (en) 2005-12-21 2006-12-20 Anti-viral compounds

Publications (1)

Publication Number Publication Date
ATE541844T1 true ATE541844T1 (de) 2012-02-15

Family

ID=38226308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06848055T ATE541844T1 (de) 2005-12-21 2006-12-20 Antivirale verbindungen

Country Status (14)

Country Link
US (1) US7910595B2 (de)
EP (1) EP1979348B1 (de)
JP (1) JP2009521479A (de)
KR (1) KR20080080395A (de)
CN (1) CN102702193A (de)
AT (1) ATE541844T1 (de)
AU (1) AU2006330924B2 (de)
CA (1) CA2633757A1 (de)
ES (1) ES2378473T3 (de)
IL (1) IL192306A0 (de)
NZ (1) NZ569817A (de)
RU (1) RU2441869C2 (de)
WO (1) WO2007076034A2 (de)
ZA (1) ZA200805304B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081517A2 (en) * 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
US8236950B2 (en) * 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2550755T3 (es) 2007-08-03 2015-11-12 Romark Laboratories, L.C. Compuestos de tiazolida sustituidos con alquilsulfonilo
MX2010013842A (es) * 2008-07-03 2011-01-14 Merck Patent Gmbh Naftiridinonas como inhibidores de aurora cinasa.
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
SG172352A1 (en) * 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
MX2011010047A (es) * 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010114881A1 (en) * 2009-04-01 2010-10-07 Progenra Inc. Anti-neoplastic compounds, compositions and methods
MX2011010218A (es) 2009-04-02 2011-10-10 Merck Patent Gmbh Inhibidores de autotaxina.
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
NZ596538A (en) * 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
WO2011046991A2 (en) * 2009-10-15 2011-04-21 Gilead Connecticut, Inc. Certain substituted ureas as modulators of kinase activity
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドPfizer Limited 化学化合物
US20130158035A1 (en) * 2010-08-24 2013-06-20 Brigham Young University Antimetastatic compounds
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2709613B2 (de) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Verfahren zur behandlung von hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EP2950786B1 (de) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Kombinationsformulierung zweier antiviraler verbindungen
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
SG10202103278TA (en) 2013-10-14 2021-04-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2924039A1 (de) 2014-03-27 2015-09-30 Universität Zürich 2-Amino-1-phenyl-pyrrolo[3,2-b]chinoxalin-3-carboxamid-Derivate
BR112016029756B1 (pt) 2014-06-27 2021-05-04 Agro-Kanesho Co., Ltd método para produzir um composto
HK1246593A1 (zh) * 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
RU2601309C1 (ru) * 2015-07-21 2016-11-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации, ГБОУ ВПО ВолгГМУ МЗ РФ Улучшенный способ получения хлорангидридов гидроксибензойных кислот
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US10239875B2 (en) 2017-06-16 2019-03-26 King Saud University Naphthyridinyl hydrazine derivatives as potent peripheral analgesic agents
EP3684361A4 (de) 2017-09-20 2021-09-08 Kura Oncology, Inc. Substituierte inhibitoren von menin-mll und verfahren zur verwendung
GB201809460D0 (en) 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
GB201809458D0 (en) 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
AU2020327013B2 (en) 2019-08-08 2026-03-26 Les Laboratoires Servier A method for preparing Ivosidenib and an intermediate thereof
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4294806A1 (de) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2-inhibitoren und verwendungen davon
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
US3021332A (en) * 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
DE3643456A1 (de) * 1986-12-19 1988-06-23 Bayer Ag Cyan-trichlor-pyrido-pyrimidin
ES2009217A6 (es) * 1987-07-07 1989-09-16 Guillermo Tene Lab Morrith S A Procedimiento de obtencion de 4-amino derivados de 2-metiltio-pirido-(2,3d) pirimidinas.
GB8912336D0 (en) 1989-05-30 1989-07-12 Smithkline Beckman Intercredit Compounds
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
GB9127252D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
GB9312891D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
BR9607089A (pt) * 1995-11-14 1997-11-11 Pharmacia & Upjohn Spa Compostos de pirimidina condensada biciclica composição farmacéutica utilização e produtos que contém os mesmos e processo para a preparação desses compostos
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
FR2751330B1 (fr) 1996-07-16 1998-10-30 Pernod Ricard Procede de production de derivees de diol-1,3 naturels et de derives de 1,3-dioxane naturels correspondants
BR9710808A (pt) 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO1998013350A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
DE19647317A1 (de) 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
DE19647413A1 (de) 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
WO1998023613A1 (en) 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
SK141799A3 (en) * 1997-04-16 2000-08-14 Abbott Lab 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors
WO1999043691A1 (en) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
BR9815899A (pt) 1998-05-20 2001-02-20 Lilly Co Eli Compostos antivirais
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
CN1212861C (zh) * 1999-09-17 2005-08-03 第一三得利制药株式会社 以NF-κB抑制剂为有效成分的心肌炎、扩张型心肌病和心衰的预防或治疗药
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
WO2001057040A1 (en) 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
KR20030005197A (ko) 2000-02-18 2003-01-17 샤이어 바이오켐 인코포레이티드 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Rho−キナーゼ阻害剤
HUP0500200A2 (hu) * 2002-01-17 2005-07-28 Neurogen Corporation Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
JP2003321472A (ja) * 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
US7037913B2 (en) 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
AU2003229305A1 (en) * 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
ATE404537T1 (de) 2002-08-13 2008-08-15 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
US20050075331A1 (en) 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
WO2004047818A2 (en) 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
EP1569925A1 (de) * 2002-12-13 2005-09-07 Neurogen Corporation 2-substituierte chinazolin-4-ylamin analoge verbindungen als capsaicin receptor modulatoren
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
TW200508224A (en) * 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7223766B2 (en) 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
BRPI0410720A (pt) 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
TW200510373A (en) 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
US20070105865A1 (en) * 2003-09-09 2007-05-10 Neurogen Corporation Substituted bicyclic quinazolin-4-ylamine derivatives
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
JP2007509985A (ja) * 2003-10-31 2007-04-19 ニューロジェン・コーポレーション カプサイシン受容体作動薬
GB0326168D0 (en) 2003-11-10 2003-12-17 Arrow Therapeutics Ltd Chemical compounds
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
GB0326963D0 (en) * 2003-11-19 2003-12-24 Glaxo Group Ltd Compounds
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
CN1950081A (zh) * 2004-03-04 2007-04-18 神经能质公司 芳烷氨基取代的喹唑啉类似物
JP2007534735A (ja) 2004-04-28 2007-11-29 アロウ セラピューティクス リミテッド 抗ウイルス剤として使用するためのモルホリニルアニリノキナゾリン誘導体
CN1976944A (zh) 2004-06-30 2007-06-06 默克公司 雌激素受体调节剂
KR20070058602A (ko) 2004-09-30 2007-06-08 티보텍 파마슈티칼즈 리미티드 Hcv 저해 바이-사이클릭 피리미딘
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
JP2008525422A (ja) * 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US8030318B2 (en) * 2005-03-25 2011-10-04 Tibotec Pharmaceuticals Ltd. Fused bicyclic inhibitors of HCV
CN101189234B (zh) * 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
TW200716631A (en) * 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
US7816351B2 (en) 2005-09-23 2010-10-19 Equispharm Co., Ltd 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
JP5161102B2 (ja) * 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド mTOR阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
CA2633541A1 (en) * 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
EP1979349B1 (de) 2005-12-21 2010-07-28 Abbott Laboratories Antivirale verbindungen
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds

Also Published As

Publication number Publication date
WO2007076034A2 (en) 2007-07-05
ES2378473T3 (es) 2012-04-12
JP2009521479A (ja) 2009-06-04
HK1122291A1 (en) 2009-05-15
AU2006330924B2 (en) 2012-03-15
RU2441869C2 (ru) 2012-02-10
US7910595B2 (en) 2011-03-22
CN102702193A (zh) 2012-10-03
WO2007076034A3 (en) 2007-10-04
CA2633757A1 (en) 2007-07-05
NZ569817A (en) 2011-10-28
AU2006330924A1 (en) 2007-07-05
ZA200805304B (en) 2012-01-25
KR20080080395A (ko) 2008-09-03
EP1979348B1 (de) 2012-01-18
EP1979348A2 (de) 2008-10-15
IL192306A0 (en) 2008-12-29
US20070232627A1 (en) 2007-10-04
RU2008129810A (ru) 2010-01-27

Similar Documents

Publication Publication Date Title
ATE541844T1 (de) Antivirale verbindungen
ATE475660T1 (de) Antivirale verbindungen
WO2007081517A3 (en) Anti-viral compounds
WO2008133753A3 (en) Anti-viral compounds
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
EA200700243A1 (ru) Способы лечения гепатита с
EA200900298A1 (ru) Ингибиторы вируса гепатита с
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
NO20090453L (no) Hepatitt C Virusinhibitorer
DK1987038T3 (da) HCV NS5B-hæmmere
EA200900969A1 (ru) Макроциклические ингибиторы протеазы гепатита с
EA200701849A1 (ru) Пролекарственные соединения трициклических нуклеозидов, фармацевтическая композиция на их основе и способ лечения и/или ингибирования вирусной инфекции у млекопитающего
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
ATE551337T1 (de) Inhibitoren des hepatitis-c-virus
NO20073105L (no) Pyridazinonforbindelser
EA200901241A1 (ru) Соединения для лечения гепатита с
EA200701669A1 (ru) Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA201000277A1 (ru) Соединения для лечения гепатита с